Judy Kim, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Apellis
    Topic:
    geographic atrophy
    Date added:
    11/15/2024
    Date updated:
    11/15/2024
    Relationship end date:
    05/08/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Amgen
    Topic:
    biosimilar
    Date added:
    11/15/2024
    Date updated:
    11/15/2024
    Relationship end date:
    10/24/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Adverum
    Topic:
    biosimilar
    Date added:
    11/15/2024
    Date updated:
    11/15/2024
    Relationship end date:
    09/28/2024
  • Type of financial relationship:
    Independent contractor
    Ineligible company:
    Alimera Sciences
    Topic:
    Steroid
    Date added:
    11/15/2024
    Date updated:
    11/15/2024
    Relationship end date:
    10/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Bausch and Lomb
    Topic:
    Vitrectomy
    Date added:
    11/15/2024
    Date updated:
    11/15/2024
    Relationship end date:
    01/31/2026
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Clearside
    Topic:
    suprachoroidal injection
    Date added:
    11/15/2024
    Date updated:
    11/15/2024
    Relationship end date:
    07/01/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Eyepoint
    Topic:
    Clinical Trial data
    Date added:
    11/15/2024
    Date updated:
    11/15/2024
    Relationship end date:
    12/31/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Neurotech
    Topic:
    Neuroprotection clinical trial data
    Date added:
    11/15/2024
    Date updated:
    11/15/2024
    Relationship end date:
    04/03/2025
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Novartis
    Topic:
    Brolucizumab
    Date added:
    11/15/2024
    Date updated:
    11/15/2024
    Relationship end date:
    05/02/2023
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    outlook therapeutics
    Topic:
    avastin
    Date added:
    11/15/2024
    Date updated:
    11/15/2024
    Relationship end date:
    07/17/2024

Pages

Return to Ophthalmology at the Crossroads 2024 (RP2412D)

 

**Disclaimer**

This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.